<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Genetic Analysis Helps Maximize Clinical Benefit with PARP Inhibitors in BRCA+ Ovarian Cancer

Default sub title

minute read

Written by OncLive on January 17, 2023

Using genetic testing to identify BRCA mutations in ovarian cancer can help inform the selection of frontline maintenance therapies and manage toxicities.

Topics: Press Coverage

Comments

Related Stories